Proteinase-activated receptor-2-triggered prostaglandin E2 release, but not cyclooxygenase-2 upregulation, requires activation of the phosphatidylinositol 3-kinase / akt / nuclear factor-κB pathway in human alveolar epithelial cells

Journal of Pharmacological Sciences

Volumn 111, Issue 3, 2009, Pages 269-275

  Moriyuki, Kazumi ^a   Sekiguchi, Fumiko ^a   Matsubara, Kaori ^a   Nishikawa, Hiroyuki ^b   Kawabata, Atsufumi ^a  

^a KINKI UNIVERSITY   (Japan)

^b Fuso Pharmaceutical Industries Ltd   (Japan)

Author keywords

Cyclooxygenase 2 (COX 2); Human alveolar epithelial cell line a549; Nuclear factor B (NF B); Proteinase activated receptor 2 (PAR2)

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 2; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG ALVEOLUS EPITHELIUM; PROSTAGLANDIN RELEASE; SIGNAL TRANSDUCTION; STIMULATION; UPREGULATION;

EID: 73349118776     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09155FP     Document Type: Article

References (35)

1. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53:245-282.
2. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A. 1994;91:9208-9212.
3. Mirza H, Schmidt VA, Derian CK, Jesty J, Bahou WF. Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell alpha-or beta-tryptases. Blood. 1997;90:3914-3922.
4. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000;97:5255-5260.
5. Sekiguchi F, Kawabata A. Protease-activated receptors (PARs) as therapeutic targets: development of agonists /antagonists and modulation of gastrointestinal functions. Drug Des Rev-Online. 2004;1:287-296.
6. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev. 2005;26:1-43.
7. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Blaber M, et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem. 2006;387:817-824.
8. Cocks TM, Moffatt JD. Protease-activated receptors: sentries for inflammation? Trends Pharmacol Sci. 2000;21:103-108.
9. Larsen AK, Seternes OM, Larsen M, Aasmoe L, Bang B. Salmon trypsin stimulates the expression of interleukin-8 via protease-activated receptor-2. Toxicol Appl Pharmacol. 2008; 230:276-282.
10. Schmidlin F, Amadesi S, Dabbagh K, Lewis DE, Knott P, Bunnett NW, et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol. 2002;169:5315-5321.
11. Kawabata A, Kawao N. Physiology and pathophysiology of proteinase-activated receptors (PARs): PARs in the respiratory system: cellular signaling and physiological /pathological roles. J Pharmacol Sci. 2005;97:20-24.
12. Takizawa T, Tamiya M, Hara T, Matsumoto J, Saito N, Kanke T, et al. Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin content in protease-activated receptor 2-deficient mice. J Pharmacol Sci. 2005;98:99-102.
13. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002;161:1903-1915.
14. Moussa L, Apostolopoulos J, Davenport P, Tchongue J, Tipping PG. Protease-activated receptor-2 augments experimental crescentic glomerulonephritis. Am J Pathol. 2007;171:800-808.
15. Kawagoe J, Takizawa T, Matsumoto J, Tamiya M, Meek SE, Smith AJ, et al. Effect of protease-activated receptor-2 deficiency on allergic dermatitis in the mouse ear. Jpn J Pharmacol. 2002;88:77-84.
16. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, et al. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003;111:35-41.
17. 2 release from human respiratory epithelial cells. J Immunol. 2002;168:3577-3585.
18. 2 formation in human lung epithelial cells. J Pharmacol Exp Ther. 2005;315:576-589.
19. Moriyuki K, Nagataki M, Sekiguchi F, Nishikawa H, Kawabata A. Signal transduction for formation /release of interleukin-8 caused by a PAR2-activating peptide in human lung epithelial cells. Regul Pept. 2008;145:42-48.
20. Adam E, Hansen KK, Astudillo Fernandez O, Coulon L, Bex F, Duhant X, et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J Biol Chem. 2006;281:6910-6923.
21. 2-COX-1-microsomal PGE synthase-1 cascade in human lung epithelial cells. Cell Biochem Funct. 2008;26:279-282.
22. Wang H, Wen S, Bunnett NW, Leduc R, Hollenberg MD, MacNaughton WK. Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein. J Biol Chem. 2008; 283:809-815.
23. Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 2002;16:1053-1068.
24. Baetz D, Shaw J, Kirshenbaum LA. Nuclear factor-kappaB decoys suppress endotoxin-induced lung injury. Mol Pharmacol. 2005;67:977-979.
25. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82-85.
26. Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem. 2006;281:11792-11804.
27. N'Guessan PD, Etouem MO, Schmeck B, Hocke AC, Scharf S, Vardarova K, et al. Legionella pneumophila-induced PKCalpha-, MAPK-, and NF-kappaB-dependent COX-2 expression in human lung epithelium. Am J Physiol Lung Cell Mol Physiol. 2007;292:L267-L277.
28. Li Q, Guo Y, Tan W, Ou Q, Wu WJ, Sturza D, et al. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-kappaB dependent pathway. Circulation. 2007;116:1577-1584.
29. Billack B, Heck DE, Mariano TM, Gardner CR, Sur R, Laskin DL, et al. Induction of cyclooxygenase-2 by heat shock protein 60 in macrophages and endothelial cells. Am J Physiol Cell Physiol. 2002;283:C1267-C1277.
30. Pham H, Shafer LM, Slice LW. CREB-dependent cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression is mediated by protein kinase C and calcium. J Cell Biochem. 2006;98:1653-1666.
31. 2 synthesis. J Immunol. 1997; 159:391-400.
32. 2 synthesis via nuclear factor-kappaB. Am J Respir Crit Care Med. 2003;168:692-699.
33. Uto T, Fujii M, Hou DX. 6-(Methylsulfinyl)hexyl isothiocyanate suppresses inducible nitric oxide synthase expression through the inhibition of Janus kinase 2-mediated JNK pathway in lipopolysaccharide-activated murine macrophages. Biochem Pharmacol. 2005;70:1211-1221.
34. Morsy MA, Isohama Y, Miyata T. Prostaglandin E2 increases surfactant secretion via the EP1 receptor in rat alveolar type II cells. Eur J Pharmacol. 2001;426:21-24.
35. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol. 2007;293:L259-L271.